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ORIGINAL ARTICLE
Association of serum uric acid with high-sensitivity C-reactive protein in
postmenopausal women
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aThe Persian Gulf Tropical Medicine Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran; bThe Persian Gulf Marine
Biotechnology Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran
ABSTRACT
Objectives: To explore the independent correlation between serum uric acid and low-grade inflamma-
tion (measured by high-sensitivity C-reactive protein, hs-CRP) in postmenopausal women.
Methods: A total of 378 healthy Iranian postmenopausal women were randomly selected in a popula-
tion-based study. Circulating hs-CRP levels were measured by highly specific enzyme-linked immuno-
sorbent assay method and an enzymatic calorimetric method was used to measure serum levels of
uric acid. Pearson correlation coefficient, multiple linear regression and logistic regression models were
used to analyze the association between uric acid and hs-CRP levels.
Results: A statistically significant correlation was seen between serum levels of uric acid and log-trans-
formed circulating hs-CRP (r¼ 0.25, p< 0.001). After adjustment for age and cardiovascular risk factors
(according to NCEP ATP III criteria), circulating hs-CRP levels were significantly associated with serum
uric acid levels (b ¼ 0.20, p< 0.001). After adjustment for age and cardiovascular risk factors, hs-CRP
levels 3mg/l were significantly associated with higher uric acid levels (odds ratio ¼1.52, 95% confi-
dence interval 1.18–1.96).
Conclusion: Higher serum uric acid levels were positively and independently associated with circulat-
ing hs-CRP in healthy postmenopausal women.
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Introduction
Numerous studies have clearly established that C-reactive
protein (CRP) as a marker of low-grade inflammation can pre-
dict future coronary artery disease in apparently healthy per-
sons1,2. In a large and comprehensive meta-analysis, the
Emerging Risk Factor Collaboration reported that CRP con-
centration had continuous associations with subsequent risk
of coronary heart disease, ischemic stroke, and deaths from
vascular and non-vascular diseases3. CRP is not only a bio-
marker for prediction of cardiovascular diseases but also has
direct effects in atherosclerotic mechanisms because it is pre-
sent in atherosclerotic plaques4.
Recent experimental, clinical, and epidemiological studies
have shown that hyperuricemia may cause endothelial dys-
function and pathologic vascular remodeling, and hence play
a role in the pathogenesis of hypertension and progressive
renal failure, cardiovascular diseases, stroke, chronic heart
failure, type 2 diabetes mellitus, insulin resistance and the
metabolic syndrome5–11.
Uric acid may have direct proinflammatory effects on vas-
cular smooth muscle cells (VSMCs) because soluble uric acid
induces inflammatory pathways in rat VSMCs in vitro12.
Therefore, it has been suggested that uric acid may play a
role in vascular changes associated with cardiovascular
diseases12. In mice studies, it has been shown that hyperuri-
cemia may trigger production of proinflammatory cytokines
such as tumor necrosis factor-a (TNF-a)13. Soluble uric acid
induces CRP mRNA expression in human vascular endothelial
and smooth muscle cells with a concomitant increase in CRP
release into cell culture media5.
Although remarkable common features in vascular
changes have been shown for uric acid and CRP in vitro stud-
ies5,12,13, there are few population-based studies in medical
literature to reveal the association between uric acid levels
and inflammatory biomarkers14–17. A statistically significant
positive crude correlation between CRP and uric acid was
found in a German population-based study14. A positive and
significant association between uric acid levels and inflamma-
tory biomarkers including CRP, TNF-a and IL-6 was reported
among older persons15.
There are no clear data on whether the relationship
between uric acid and low-grade inflammation is significant
when other vascular risk factors are considered18. However,
the significant association between uric acid and CRP per-
sisted after controlling for potential confounders such as
body mass index16 and metabolic syndrome17. The present
population-based study sought to explore the independent
correlation between serum uric acid and low-grade inflamma-
tion (measured by hs-CRP) in postmenopausal women.
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Methods
Community sampling and physical examinations
The study design has been described elsewhere19. Briefly,
participants in the present study were an age-stratified ran-
dom sample of 378 postmenopausal women who partici-
pated in the extension part of the Iranian Multicentral
Osteoporosis Study (IMOS). The subjects were randomly
selected from 13 clusters in the port city of Bushehr (the cap-
ital of Bushehr Province, southern part of Iran). All of the
women, who were community-dwelling and ambulatory,
were asked to fast and to come to the survey center
between 07.30 and 09.30. Blood pressure was assessed twice
at the right arm after a 15-min rest in the sitting position,
using a standard mercury sphygmomanometer. Height was
measured using a stadiometer and weight was measured
after removing heavy outer garments and shoes, and body
mass index (BMI) was calculated as weight (kg) divided by
squared height in meters.
Laboratory measurements
Fasting blood samples were taken and promptly centrifuged
and separated, and analyses were carried out at the Persian
Gulf Health Research Center on the day of blood collection
using a Selectra 2 autoanalyzer (Vital Scientific, Spankeren,
Netherlands). An enzymatic, calorimetric method was used to
measure serum levels of uric acid using Toos commercial kit
(Pars Azmun Inc., Tehran, Iran). Glucose was assayed by the
enzymatic (glucose oxidase) colorimetric method using a
commercial kit (Pars Azmun Inc., Tehran, Iran). Serum total
cholesterol and high density lipoprotein (HDL) cholesterol
were measured using a cholesterol oxidase phenol aminoan-
tipyrine; triglycerides were measured using a glycerol-3 phos-
phate oxidase phenol aminoantipyrine enzymatic method.
Serum low density lipoprotein (LDL) cholesterol was calcu-
lated using the Friedewald formula; LDL cholesterol was
not calculated when the triglyceride concentration was
>400mg/dl.
CRP was measured by using CRP HS enzyme-linked
immunosorbent assay (ELISA) (DRG International), a hs-CRP
assay. A concentration of 0.1mg/l for CRP was estimated to
be the lowest detectable concentration in the CRP HS ELISA
assay. According to inter-assay coefficient of variation <20%,
the functional sensitivity of CRP measurement was deter-
mined to be 0.1mg/l.
Definitions
Using the American Diabetes Association criteria, either a
fasting plasma glucose level 126mg/dl or use of anti-dia-
betic measures was defined as diabetes20. A subject was con-
sidered hypertensive if her blood pressure was at least 140/
90mmHg. The cut-off points of serum total cholesterol, HDL
cholesterol and LDL cholesterol, and serum triglyceride distri-
butions used to assign subjects to different levels of risk
were derived from the National Cholesterol Education
Program (NCEP) guidelines in the United States (Adult
Treatment Panel, ATP III)21.
Statistical analysis
The distribution of variables was studied using probability
plots and the Shapiro–Wilk test. It was found that log trans-
formation of hs-CRP levels was a better fit to a Gaussian distri-
bution. The geometric mean for those biochemical variables
was defined as the arithmetic mean of the log-transformed
data ± standard deviation, raised to the power of 10.
A two-tailed independent group t-test was used to com-
pare the mean values across groups. Pearson’s correlation
coefficient was used to study the relationships between log-
transformed hs-CRP and uric acid values. A partial correlation
analysis was performed to assess the association between
uric acid and hs-CRP levels, adjusted for age and BMI.
Multiple linear regression models were used to assess the
association between uric acid levels (independent variables)
and hs-CRP levels (dependent variable); in the full model, car-
diovascular risk factors (according to NCEP, ATP III criteria)
were considered as covariates.
The binary multiple logistic regression model was used to
ascertain the associations between circulating hs-CRP
(3mg/l versus <3mg/l) and uric acid levels; cardiovascular
risk factors (according to NCEP ATP III criteria) were consid-
ered covariates. According to the clinical guidelines issued by
the American Heart Association and the Centers for Disease
Control and Prevention, levels of hs-CRP of more than 3mg/l
was considered as higher cardiovascular risk22.
A p value lower than 0.05 was accepted as significant. All
statistical analyses were performed using PASW Statistics
GradPack 18 (SPSS Inc., Chicago, IL, USA).
Results
The mean age (± standard deviation) of the women was
58.78 ± 7.82 years. The participants (378 postmenopausal
women) were stratified into low (lower than or equal to the
median) and high (higher than the median) serum uric acid
groups. Table 1 shows the baseline characteristics of the
studied postmenopausal women, stratified by uric acid
groups. Women with high uric acid levels had higher BMI
and hs-CRP levels than women with low uric acid levels.
Uric acid levels were significantly correlated with circulat-
ing hs-CRP in the studied population (r¼ 0.25, p< 0.001).
Figure 1 illustrates the scatterplot and linear prediction fit
line of log-transformed hs-CRP and uric acid levels. This cor-
relation persisted after adjustment for age (r¼ 0.27,
p< 0.001) and BMI (r¼ 0.20, p< 0.001).
By dichotomization of hs-CRP levels to 3mg/l and
<3mg/l, we found that postmenopausal women with hs-CRP
levels 3mg/l had significantly higher circulating uric
acid levels than those with hs-CRP levels <3mg/l
(5.08 ± 1.23mg/dl vs. 4.50 ± 0.96mg/dl, p< 0.0001).
In multiple linear regression analysis, after adjustment for
age, type 2 diabetes mellitus, hypertension, obesity and dysli-
pidemia, circulating hs-CRP levels were significantly
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correlated with serum uric acid levels (b ¼ 0.20, p< 0.001)
(Table 2).
After adjustment for potential confounders including clas-
sical cardiovascular risk factors, hs-CRP levels 3mg/l were
significantly associated with higher uric acid levels in the
multivariable logistic regression model (odds ratio ¼1.52,
95% confidence interval 1.18–1.96, p¼ 0.001).
Discussion
In a population-based study, we showed a strong correlation
between serum uric acid and hs-CRP in Iranian postmeno-
pausal women, independent of cardiovascular risk factors.
Similar findings were reported from a National Health and
Nutrition Survey in Germany14, from a representative Italian
cohort of persons aged 65–95 years15, from a population-
based study in Switzerland16, and in health examinations
among employed subjects in Brazil17. Ruggiero and col-
leagues15 found a progressive increase in frequency of sub-
jects with abnormal levels of IL-6 and CRP in community-
dwelling older persons. In contrast, circulating uric acid was
not associated with inflammatory markers in elderly men in
Taiwan23.
Although the findings of the current study and other
cross-sectional studies could not illustrate whether uric acid
is a causal risk factor for hs-CRP and vascular disease,
Ruggiero and colleagues24 found that baseline uric acid lev-
els and changes in circulating uric acid predicted a 3-year
change in CRP in a cohort of Italian men and women aged
21–98 years. In in vitro studies, it has been shown that uric
acid could induce expression of CRP in smooth muscle cells
and vascular endothelial cells5. Uric acid-induced CRP expres-
sion and vascular remodeling suggest a role for uric acid in
hypertension and cardiovascular diseases5. In male and
female subjects, CRP and uric acid were consistently associ-
ated with an increase in arterial stiffness25.
We found that the association between uric acid and hs-
CRP still remained significant after adjustment for BMI. This
finding is consistent with data of Keenan and colleagues17.
These findings suggest that uric acid might be independently
related to hs-CRP and this association is beyond obesity.
However, in the population-based Colaus study, the associ-
ation between uric acid and CRP was attenuated upon
further adjustment for BMI16.
In prospective studies, it has been shown that hs-CRP
levels 3mg/l are associated with increased cardiovascular
risk26. Ridker and colleagues27 reported CRP as a stronger
predictor of cardiovascular events than LDL cholesterol level
in apparently healthy American women who were followed
for a mean of 8 years. In the current study, we found that
postmenopausal women with hs-CRP levels 3mg/l had sig-
nificantly higher uric acid levels, and hs-CRP levels 3mg/l
were positively and significantly associated with circulating
uric acid, independent of established cardiovascular risks.
These findings were consistent with the study results of
Keenan and colleagues17 who found the highest versus low-
est uric acid quartile was associated with hs-CRP levels
3mg/l after adjusting for traditional cardiovascular risk fac-
tors. Therefore, one could speculate that uric acid and hs-
CRP levels might be equivalent to each other. In fact, in the
Bezafibrate Infarction Prevention (BIP) trial, uric acid and CRP
measurements provided similar prognostic information for
risk stratification of patients with coronary artery disease28. In
addition, combined assessment of uric acid and CRP levels
provides incremental information for risk assessment of car-
diac events in patients with coronary artery disease28.
The data from current experimental and population-based
studies are in line with the hypothesis that uric acid stimu-
lates vascular smooth muscles to produce proinflammatory
markers including CRP that have a direct role in the inflam-
matory cascade associated with atherosclerosis. Hence, it is
not surprising that the available evidence is going to
Figure 1. Scatterplot of log hs-CRP and uric acid and fitted values in postmeno-
pausal women.
Table 2. Multiple linear regression analysis for the association between circu-
lating hs-CRP (dependent variable) and serum uric acid levels (independent
variable) in different models. Full model included serum uric acid, type 2 dia-
betes mellitus, hypertension, obesity and dyslipidemia.
b p Value
Unadjusted 0.25 <0.001
Age-adjusted 0.27 <0.001
Age-, body mass index-adjusted 0.27 <0.001
Full model 0.20 <0.001
Table 1. The general characteristics, including blood pressure, anthropometric
measurements, and the biochemical parameters of postmenopausal women,
stratified by serum uric acid levels below/equal or above median. Data are
given as mean ± standard deviation.
Uric acid below or
equal to median
Uric acid
above median p Value
Age (years) 58.04 ± 7.33 59.59 ± 8.58 0.081
Body mass index (kg/m2) 27.49 ± 4.67 29.34 ± 4.74 <0.001
Systolic blood pressure (mmHg) 125.26 ± 19.61 127.27 ± 19.97 0.361
Diastolic blood pressure (mmHg) 78.51 ± 10.71 81.15 ± 25.91 0.232
Total cholesterol (mg/dl) 230.41 ± 45.80 236.64 ± 47.83 0.245
High density lipoprotein
cholesterol (mg/dl)
41.61 ± 10.36 40.42 ± 11.09 0.317
Low density lipoprotein
cholesterol (mg/dl)
153.29 ± 41.61 157.71 ± 42.68 0.345
Triglyceride (mg/dl) 177.58 ± 93.83 191.75 ± 100.85 0.191
Fasting blood glucose (mg/dl) 116.85 ± 54.64 180.86 ± 38.34 0.128
hs-CRP (mg/l) 1.36 ± 2.75a 2.60 ± 2.60a <0.001
a, Geometric mean± standard deviation
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establish a causal link between hyperuricemia and cardiovas-
cular outcomes29,30. However, clinical trials are needed to
assess the relevance of apparently sustained falls in hs-CRP
after the use of uric acid-lowering drugs as well as apparent
decreases in cardiovascular outcomes and mortality. The
Serum Urate Reduction to Prevent Hypertension (SURPHER)
study, a double-blinded, cross-over trial on adults 18–40
years old, has now been launched to determine potential for
urate-lowering therapies to decrease blood pressure and CRP
levels31.
The strengths of this study are its population-based
design, existing information about cardiometabolic risk con-
ditions of the participants for their adjustment as confound-
ers in regression models, and particularly addressing
postmenopausal women for the first time who have higher
serum uric acid levels32. However, we acknowledge several
study limitations. A causal relationship between uric acid and
hs-CRP could not be clarified in our cross-sectional study. We
assessed uric acid and hs-CRP with single measurements, and
therefore changes in circulating uric acid and this acute-
phase reactant over time could not be reflected in our study.
Although this study is the first population-based study that
has investigated a link between circulating uric acid and hs-
CRP in menopause, its findings should be confirmed in fur-
ther human studies with larger samples. Finally, to elucidate
the complex system that regulates uric acid and low-grade
inflammation, the concurrent measurement of additional
inflammatory markers and cytokines, including TNF-a and
IL-6, merits consideration.
In conclusion, our findings comply with those of previous
population-based studies showing an independent positive
association between uric acid levels and low-grade inflamma-
tion as measured by hs-CRP. Clinical trials are needed to
assess the relevance of apparently sustained falls in hs-CRP
after the use of uric acid-lowering drugs as well as apparent
decreases in cardiovascular outcomes and mortality.
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